Clinical trials
Dermatomyositis clinical trials
Below are recruiting dermatomyositis clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07486869RecruitingPhase 2
Emapalumab study for MDA5-related lung disease
This trial tests if emapalumab can help people with a serious lung condition linked to MDA5 antibodies. It may be an option for those with worsening breathing despite other treatments.
Miami, FloridaAges 18 years+ - NCT07111065RecruitingPhase 2
Fatty Acid Supplement for Dermatomyositis
This study tests whether taking a fatty acid supplement (omega-3) for 6 months can help reduce disease activity in people with dermatomyositis. Participants will also receive dietary coaching and have regular check-ups at the NIH to monitor their progress.
Bethesda, MarylandAges 18–60 - NCT06686524RecruitingPhase 1
CD19-targeted UCAR-T for refractory juvenile dermatomyositis
This trial tests a new type of immune cell therapy (UCAR-T) that targets a protein called CD19 to treat children with a severe form of juvenile dermatomyositis that hasn't responded to standard treatments. It aims to calm the overactive immune system and reduce symptoms like muscle weakness and skin rashes.
Hangzhou, ZhejiangAges 5 years+ - NCT07037472Recruiting
Imaging calcium deposits in dermatomyositis patients
This study uses a special imaging technique (photoacoustic/ultrasound) to look at calcium deposits under the skin in people with dermatomyositis. It aims to find patterns that help doctors understand the condition and track how well treatments work.
BeijingAges 18–80 - NCT07374107Recruiting
Patient insights for shaping myositis research
This study asks people with autoimmune muscle diseases (myositis) and their caregivers to share their experiences and insights. By joining, you help shape better research and care for myositis.
New Orleans, LouisianaAges 7 years+ - NCT02945345Recruiting
Test how skin scores change in cutaneous dermatomyositis
This study looks at how well skin symptoms improve in adults with cutaneous dermatomyositis by using a specific skin-scoring tool. The results may help doctors better measure treatment response and guide care.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06203249Recruiting
Exploring lung health and immune system in a rare muscle disease
This trial looks at how the immune system and tiny organisms in the lungs may affect a rare condition called anti-MDA5 positive dermatomyositis, which can cause serious lung disease. It may help doctors understand why some patients get worse quickly and how to better treat them.
Beijing, Beijing MunicipalityAges 18–100 - NCT04972760RecruitingPhase 3
Baricitinib for active dermatomyositis in adults
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
ParisAges 18–64 - NCT06004817Recruiting
Dermatomyositis severity in children and adults
This study looks at how severe dermatomyositis is in people who develop it as children or adults. It aims to better understand the disease and may help guide future treatments.
NancyAges Any age - NCT06154252RecruitingPhase 2/Phase 3
Study of CABA-201 for active myositis in adults and children
This trial tests a new treatment called CABA-201, which uses your own immune cells modified to attack the overactive cells causing myositis. It is for people with active disease that hasn't improved enough with standard therapies.
Orange, CaliforniaAges 6–75 - NCT06298019RecruitingPhase 1
CAR T-cell therapy for tough dermatomyositis
This study tests a new immune therapy called CAR T-cells (KYV-101) for people with active, tough-to-treat dermatomyositis. It aims to see if the treatment is safe and can reduce muscle weakness and skin rash.
Palo Alto, CaliforniaAges 25–72 - NCT06455449RecruitingPhase 3
Injectable anifrolumab for polymyositis or dermatomyositis
This study tests a new injectable medicine (anifrolumab) added to your usual treatments for polymyositis or dermatomyositis. It may help reduce disease activity if you have moderate to severe symptoms and are already on stable therapy.
Phoenix, ArizonaAges 18–75 - NCT06569472RecruitingPhase 1
CAR-T cell therapy for tough juvenile dermatomyositis
This trial tests a treatment using your own immune cells, modified to target a protein called CD19, for children and teens with juvenile dermatomyositis that hasn't gotten better with standard treatments. The goal is to see if this therapy can help calm the inflammation and improve symptoms.
Hangzhou, ZhejiangAges 5–17 - NCT06857240RecruitingPhase 2
Ruxolitinib cream for stubborn skin in dermatomyositis
This trial tests a cream called ruxolitinib for people with dermatomyositis whose skin symptoms haven't improved with standard treatments. It aims to see if this cream can reduce rash and activity when added to your current medications.
Cleveland, OhioAges 18–89 - NCT07160205RecruitingPhase 2/Phase 3
Study of ULSC for dermatomyositis and polymyositis
This trial tests a new treatment called ULSC to see if it can improve muscle strength and skin symptoms, and help reduce steroid use in people with dermatomyositis or polymyositis. It may be an option if standard treatments haven't worked well enough.
Gainesville, FloridaAges 18 years+ - NCT07265999Recruiting
Severity factors of dermatomyositis in Caribbean patients
This study looks at what makes dermatomyositis more severe in people of Caribbean background living in Guadeloupe. By understanding these factors, doctors may better manage this rare muscle and skin disease.
Pointe-à-PitreAges 16 years+ - NCT07345949Recruiting
Study of skin inflammation in dermatomyositis
This trial looks at a type of skin inflammation called panniculitis that can happen in people with dermatomyositis. The goal is to learn more about this condition so that better treatments can be developed.
StrasbourgAges 1 year+ - NCT01276470Recruiting
Study of environmental triggers in anti-synthetase syndrome
This study looks for environmental risk factors that may be linked to anti-synthetase syndrome, a type of inflammatory muscle disease. It compares people with the condition to carefully matched people without it, using questionnaires, blood samples, and lung imaging when needed.
Miami, FloridaAges 2–100 - NCT06438679Enrolling by invitationPhase 4
3T therapy for MDA5-positive dermatomyositis with lung involvement
This trial tests a treatment called 3T therapy for people with MDA5-positive dermatomyositis, a rare autoimmune disease that affects the skin, muscles, and often the lungs. The goal is to see if 3T therapy can help control the disease and improve lung function.
Hangzhou, ZhejiangAges 18 years+ - NCT05495321Enrolling by invitationPhase 3
Interleukin-2 for active dermatomyositis
This Phase 3 study tests whether interleukin-2 can better control “active” dermatomyositis, an inflammatory muscle and skin disease. Participants will be monitored to see if treatment improves disease activity and symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT06698796RecruitingPhase 3
Study of dazukibart for ongoing idiopathic inflammatory myopathies
This trial studies the long-term effects of dazukibart in people who completed an earlier study for idiopathic inflammatory myopathies (a group of rare conditions causing muscle inflammation and weakness). It helps researchers understand how well the medicine works over a longer period.
Glendale, ArizonaAges 18 years+ - NCT07089121RecruitingPhase 1/Phase 2
Descartes-08 for young people with autoimmune diseases
This trial tests a new therapy called Descartes-08 for children, teens, and young adults with autoimmune conditions like lupus, myasthenia gravis, or dermatomyositis. It aims to see if it can help control moderate disease that hasn't responded well enough to other treatments.
Washington D.C., District of ColumbiaAges 12 years+ - NCT06371417RecruitingPhase 1
Testing RAY121 for several immune diseases (RAINBOW trial)
This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.
Orange, CaliforniaAges 18–85 - NCT05979441Enrolling by invitationPhase 3
Long-term safety of efgartigimod injection for myositis
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
Phoenix, ArizonaAges 18 years+
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Dermatomyositis trials by city
Studies with a site in or near these metro areas.
Dermatomyositis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for dermatomyositis?
- Yes. Clin2 currently lists 42 recruiting dermatomyositis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dermatomyositis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dermatomyositis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.